These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15923115)

  • 21. HIV protease inhibitors: synthesis and activity of N-aryl-N'-hydroxyalkyl hydrazide pseudopeptides.
    Marastoni M; Baldisserotto A; Trapella C; McDonald J; Bortolotti F; Tomatis R
    Eur J Med Chem; 2005 May; 40(5):445-51. PubMed ID: 15893018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.
    Prasad JV; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hamilton HW; Hagen SE; Markoski LJ; Steinbaugh BA; Tait BD; Humblet C; Lunney EA; Pavlovsky A; Rubin JR; Ferguson D; Graham N; Holler T; Hupe D; Nouhan C; Tummino PJ; Urumov A; Zeikus E; Zeikus G; Gracheck SJ; Erickson JW
    Bioorg Med Chem; 1999 Dec; 7(12):2775-800. PubMed ID: 10658583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase.
    Sriram D; Yogeeswari P; Senchani G; Banerjee D
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2372-5. PubMed ID: 17376679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
    Smith AB; Charnley AK; Harada H; Beiger JJ; Cantin LD; Kenesky CS; Hirschmann R; Munshi S; Olsen DB; Stahlhut MW; Schleif WA; Kuo LC
    Bioorg Med Chem Lett; 2006 Feb; 16(4):859-63. PubMed ID: 16298527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-disubstituted ureas.
    Stranix BR; Sauvé G; Bouzide A; Coté A; Sévigny G; Yelle J; Perron V
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3971-4. PubMed ID: 15225709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
    Mimoto T; Nojima S; Terashima K; Takaku H; Shintani M; Hayashi H
    Bioorg Med Chem; 2008 Feb; 16(3):1299-308. PubMed ID: 17981045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and structure-activity study of shorter hexa peptide analogues as HIV-1 protease inhibitors.
    Narendra Babu SN; Rangappa KS
    Bioorg Med Chem; 2008 Jan; 16(2):874-80. PubMed ID: 17981043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies.
    Bouzide A; Sauvé G; Yelle J
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1509-13. PubMed ID: 15713418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of 3-acetyl-4-hydroxy-2-pyranone derivatives and their difluoridoborate complexes as a novel class of HIV-1 integrase inhibitors.
    Ramkumar K; Tambov KV; Gundla R; Manaev AV; Yarovenko V; Traven VF; Neamati N
    Bioorg Med Chem; 2008 Oct; 16(19):8988-98. PubMed ID: 18805696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indium-mediated atom-transfer and reductive radical cyclizations of iodoalkynes: synthesis and biological evaluation of HIV-protease inhibitors.
    Yanada R; Koh Y; Nishimori N; Matsumura A; Obika S; Mitsuya H; Fujii N; Takemoto Y
    J Org Chem; 2004 Apr; 69(7):2417-22. PubMed ID: 15049639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis of 5,6-dihydro-4-hydroxy-2-pyrones as HIV-1 protease inhibitors: the profound effect of polarity on antiviral activity.
    Hagen SE; Prasad JV; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hamilton HW; Markoski LJ; Steinbaugh BA; Tait BD; Lunney EA; Tummino PJ; Ferguson D; Hupe D; Nouhan C; Gracheck SJ; Saunders JM; VanderRoest S
    J Med Chem; 1997 Nov; 40(23):3707-11. PubMed ID: 9371233
    [No Abstract]   [Full Text] [Related]  

  • 32. Design, synthesis, and biological evaluation of novel quinoline derivatives as HIV-1 Tat-TAR interaction inhibitors.
    Chen S; Chen R; He M; Pang R; Tan Z; Yang M
    Bioorg Med Chem; 2009 Mar; 17(5):1948-56. PubMed ID: 19217787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
    Nakatani S; Hidaka K; Ami E; Nakahara K; Sato A; Nguyen JT; Hamada Y; Hori Y; Ohnishi N; Nagai A; Kimura T; Hayashi Y; Kiso Y
    J Med Chem; 2008 May; 51(10):2992-3004. PubMed ID: 18426195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitors of human immunodeficiency virus type 1 protease containing 2-aminobenzyl-substituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, activity, and oral bioavailability.
    Lehr P; Billich A; Charpiot B; Ettmayer P; Scholz D; Rosenwirth B; Gstach H
    J Med Chem; 1996 May; 39(10):2060-7. PubMed ID: 8642565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors.
    Böttcher J; Blum A; Dörr S; Heine A; Diederich WE; Klebe G
    ChemMedChem; 2008 Sep; 3(9):1337-44. PubMed ID: 18720485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and HIV protease inhibitory activity of new 4-hydroxy-2-pyrone derivatives.
    Lee YS; Kim SN; Lee YS; Lee JY; Lee CK; Kim HS; Park H
    Arch Pharm (Weinheim); 2000 Oct; 333(10):319-22. PubMed ID: 11092133
    [No Abstract]   [Full Text] [Related]  

  • 37. Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold.
    Blum A; Böttcher J; Heine A; Klebe G; Diederich WE
    J Med Chem; 2008 Apr; 51(7):2078-87. PubMed ID: 18348517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor.
    Sévigny G; Stranix B; Tian B; Dubois A; Sauvé G; Petropoulos C; Lie Y; Hellmann N; Conway B; Yelle J
    Antiviral Res; 2006 Jun; 70(2):17-20. PubMed ID: 16473417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization.
    Whiting M; Tripp JC; Lin YC; Lindstrom W; Olson AJ; Elder JH; Sharpless KB; Fokin VV
    J Med Chem; 2006 Dec; 49(26):7697-710. PubMed ID: 17181152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New hydroxyethylamine HIV protease inhibitors that suppress viral replication.
    Rich DH; Prasad JV; Sun CQ; Green J; Mueller R; Houseman K; MacKenzie D; Malkovsky M
    J Med Chem; 1992 Oct; 35(21):3803-12. PubMed ID: 1433192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.